HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN


Takeaways From Phase 1 Trial of RTX-240 in Solid Tumors: Alexander I. Spira, MD, PhD, FACP

May 10th 2022

Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial (NCT04372706) with solid tumors, presented recently at the 2022 AACR Annual Meeting.

Exploring NG-641 Plus Nivolumab for Previously Treated Metastatic or Advanced Epithelial Tumors

April 15th 2022

Already, NG-641 has shown encouraging preliminary safety and tolerability results in the ongoing phase 1a dose-escalation STAR trial (NCT04053283), which is a first-in-human study for the gene therapy.

GD2-CAR T-Cell Therapy Yields Clinical Benefit in Glioma

April 14th 2022

While the lower IV dose was generally well-tolerated, the higher dose yielded cases of serious cytokine release syndrome.

Allogeneic CAR T-Cell Therapy Shows Promise in R/R B-Cell Acute Lymphoblastic Leukemia

April 13th 2022

The phase 1, investigator-initiated trial continues to recruit participants with B-ALL.

Combination CAR T-Cell Therapy, RNA Vaccine Shows Efficacy in Solid Tumors

April 12th 2022

The novel regimen from BioNTech demonstrated encouraging results in patients with testicular or ovarian cancer.

Cord Blood Combined Natural Killer Cell Engager Therapy Shows Efficacy in Lymphoma

April 11th 2022

AFM13 is currently also being evaluated on its own in lymphoma in a phase 2 registrational study.

Trial Evaluating CAR-NK Cell Therapy in Ovarian Clear Cell Carcinoma

April 9th 2022

The first in-human phase 1 clinical trial is being conducted in Japan.

Making Antigen-Presenting Cells With Cell Squeeze Technology

July 21st 2021

The founder and chief executive officer of SQZ Biotech discussed the potential of their APC platform to treat a variety of tumors.

Advantages of Cell Squeeze Technology Over Electroporation and Viral Transfection

July 15th 2021

The founder and chief executive officer of SQZ Biotech discussed the development and advantages of their proprietary Cell Squeeze technology in creating cell therapies.